Aktuellt
SENASTE
Redeye is encouraged by the announcement that Nanexa’s clinical phase I trial with NEX-20 (NEX-20-01), a long-acting formulation of lenalidomide, has been completed. In August, we learned that the clinical phase I study with NEX-20 confirmed a release profile of lenalidomide in different doses up to 21 days. We appreciate that the completed safety and tolerability data collection supports the project’s further development. Local reactions were observed in the area of injection with NEX-20. However, Nanexa also concludes that the reactions, which ranged from mild at the lower dose levels to moderate at higher doses, all subsided during the study period. We will return with a more thorough comment in connection to the outcome of the recently announced rights issue, wherein our new base will also consider the dilutive effect of the capital injection.
LÄS MER
